CWM
EIGR

Curi Wealth Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Curi Wealth Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,500
Closed -$339K – 209
2022
Q3 		$339K Buy
+1,500
New +$369K 0.06% 124

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Curi Wealth Management's EIGR Position: Q4 2022 in Review

Curi Wealth Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2022, closing a stake of 1,500 shares — an estimated $339K sold.

Curi Wealth Management first reported a position in EIGR in Q3 2022 and held it in 1 quarter. The position peaked at $339K in Q3 2022. 81 funds tracked by Wall St. Rank hold EIGR as of Q4 2022.

  • Curi Wealth Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Curi Wealth Management sold 1,500 Eiger BioPharmaceuticals, Inc. shares in Q4 2022, an estimated $339K.
  • Curi Wealth Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q3 2022 and held it in 1 quarter.
  • Curi Wealth Management's Eiger BioPharmaceuticals, Inc. position peaked at $339K in Q3 2022.
  • 81 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2022.

Based on Curi Wealth Management's 13F filing for Q4 2022, filed 3 Feb 2023.